葛兰重金出手 9月23日，中欧基金发布关于旗下部分基金投资百利天恒非公开发行股票的公告，根据公告，葛兰 管理的中欧医疗健康混合基金认购百利天恒185.59万股，共计5.88亿元，占该基金资产净值比例 为1.8%。 牛市来了还没上车？上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限 量发放！先到先得！ 在近期的医药板块调整行情中，葛兰出手了！ 根据中欧基金公告，葛兰所管的两只基金豪掷6.79亿元，参与了创新药龙头公司百利天恒的增发。 此外，富国基金副总经理朱少醒、知名基金经理范妍等所管基金也参与了该公司的增发。从资金层 面看，在近期创新药板块的调整行情中，大量资金借道创新药主题ETF积极入市。 葛兰管理的另一只基金中欧医疗创新股票基金也认购百利天恒28.55万股，共计9050.98万元，占 该基金资产净值比例为1%。上述基金持股锁定期均为6个月。 根据基金定期报告，过去一年多来，葛兰一直在加仓百利天恒。 2024年底，中欧医疗健康混合基金持有百利天恒187.94万股，今年一季度大手笔加仓214.17万 股，二季度继续增持25.86万股，持股数量增至427.97万股。 截至今年二季度末，百 ...

在近期的医药板块调整行情中，葛兰出手了！ 根据中欧基金公告，葛兰所管的两只基金豪掷6.79亿元，参与了创新药龙头公司百利天恒的增发。此外，富国基金副总经理朱少醒、知名基金经理范妍等 所管基金也参与了该公司的增发。从资金层面看，在近期创新药板块的调整行情中，大量资金借道创新药主题ETF积极入市。 葛兰重金出手 9月23日，中欧基金发布关于旗下部分基金投资百利天恒非公开发行股票的公告，根据公告，葛兰管理的中欧医疗健康混合基金认购百利天恒185.59万 股，共计5.88亿元，占该基金资产净值比例为1.8%。 葛兰管理的另一只基金中欧医疗创新股票基金也认购百利天恒28.55万股，共计9050.98万元，占该基金资产净值比例为1%。上述基金持股锁定期均为6个 月。 | | 序号 品种代码 ⇒ | | 品种简称 | 持仓市值(元) ◆ | 占股票市值比 | 占基金净值比 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | (%) = | (%) = | | 1 | 603259.SH | 药明康德 | 46,029,135.00 | 3,201,326,33 ...

根据中欧基金公告，葛兰所管的两只基金豪掷6.79亿元，参与了创新药龙头公司百利天恒的增发。此外，富国基金副总经理朱少醒、知名基金经理范妍等 所管基金也参与了该公司的增发。从资金层面看，在近期创新药板块的调整行情中，大量资金借道创新药主题ETF积极入市。 葛兰重金出手 9月23日，中欧基金发布关于旗下部分基金投资百利天恒非公开发行股票的公告，根据公告，葛兰管理的中欧医疗健康混合基金认购百利天恒185.59万 股，共计5.88亿元，占该基金资产净值比例为1.8%。 葛兰管理的另一只基金中欧医疗创新股票基金也认购百利天恒28.55万股，共计9050.98万元，占该基金资产净值比例为1%。上述基金持股锁定期均为6个 月。 在近期的医药板块调整行情中，葛兰出手了！ | 基金名称 | 认购数量 (股) | 总成本(元) | 总成本 占基金 | 账面价值(元) | 账面价 值占基 金资产 | 锁定 | | --- | --- | --- | --- | --- | --- | --- | | | | | 资产净 | | | 期 | | | | | 值比例 | | 浄值比 | | | | | | | | 例 (%) | | ...

Core Viewpoint - The strategic collaboration among Maiwei Biotech, Yingshi Intelligent, and Haoyuan Pharmaceutical aims to develop a novel ADC compound library targeting hundreds of sites, accelerating the industrialization of innovative ADC drugs [1] Group 1: Company Collaboration - Maiwei Biotech, Yingshi Intelligent, and Haoyuan Pharmaceutical have officially announced a strategic cooperation agreement [1] - The partnership focuses on screening and advancing next-generation ADC candidate molecules [1] - The collaboration is expected to enhance the innovation and commercialization of ADC drugs [1]

Core Viewpoint - Baili Tianheng successfully raised a total of 3.764 billion yuan through a private placement of A-shares, which will accelerate the development of its innovative drug pipeline and help the company enter the ranks of entry-level multinational corporations (MNCs) [1][4] Fundraising Details - The private placement attracted participation from 18 well-known domestic and international institutions, with a share price of 317 yuan, significantly above the base price of 266.02 yuan [1][2] - The issuance was highly anticipated in the market, with 30 investors submitting bids, and the final price set at 317 yuan per share, reflecting strong confidence in the company's R&D capabilities and growth prospects [1][4] Use of Proceeds - The raised funds will be fully allocated to innovative drug research and development projects, particularly focusing on the HIRE-ADC platform and GNC platform for innovative antibody drugs [2][3] - The ADC drug development platform will advance clinical trials for six ADC drugs, targeting over ten indications, including lung cancer and breast cancer [3] Clinical Development Plans - The company is conducting over 40 clinical trials for the BL-B01D1/iza-bren drug in China and the U.S., with several indications included in breakthrough therapy designations by the FDA and CDE [3] - The GNC platform will accelerate the clinical development of multi-specific antibodies, further enriching the company's innovative drug pipeline [3] Strategic Importance - This fundraising is a key initiative in the company's "Quality Improvement, Efficiency Enhancement, and Return to Action Plan" for 2025, with a significant increase in R&D investment [4] - The successful implementation of this private placement not only reflects market recognition of the value of innovative pharmaceutical companies but also marks the company's strategic commitment to becoming a global MNC under the guidance of the "Eight Policies" [4]

Group 1 - The stock price of Baili Tianheng closed at 324.21 yuan on August 27, 2025, down by 15.79 yuan, a decrease of 4.64% from the previous trading day [1] - The company operates in the pharmaceutical and biotechnology industry, focusing on innovative drug development, particularly in the field of biopharmaceuticals [1] - Baili Tianheng has successfully developed 8 innovative ADC drugs that are currently in clinical stages, which target cancer cells to enhance treatment efficacy [1] Group 2 - Baili Tianheng and a local company, Xinyi Sheng, have set a new market capitalization record for Chengdu, with respective market values of 136.34 billion yuan and 280.27 billion yuan, achieving a "double hundred billion" market cap for Chengdu-listed companies [1] - The actual controller of the company, Zhu Yi, has a shareholding value of 101.32 billion yuan [1] - On August 27, the net inflow of main funds into Baili Tianheng was 211,600 yuan, with a cumulative net inflow of 6.7755 million yuan over the past five days [1]

Core Insights - Chengdu's local listed companies have achieved a historic milestone with two companies, Xinyi and Baili Tianheng, surpassing a market capitalization of 100 billion yuan, marking the first time the city has had "double billion" companies [1][6] - The market capitalization is a crucial indicator of a company's overall strength, and the presence of billion-yuan companies remains rare among over 5,000 listed companies in A-shares [1][6] - The ranking of Chengdu's listed companies has undergone significant changes, influenced by factors beyond just market valuation, including industry dynamics and company performance [1][6] Market Capitalization Rankings - As of August 26, the top ten Chengdu listed companies by market capitalization are: 1. Xinyi: 2802.67 billion yuan 2. Baili Tianheng: 1363.40 billion yuan 3. Tongwei: 959.82 billion yuan 4. ChuanTuo Energy: 757.51 billion yuan 5. Chengdu Bank: 756.98 billion yuan 6. Sichuan Road and Bridge: 750.81 billion yuan 7. Dongfang Electric: 675.92 billion yuan 8. Kelun Pharmaceutical: 610.46 billion yuan 9. Shenghe Resources: 413.67 billion yuan 10. Zhongwu Drone: 390.83 billion yuan [1][7] Historical Context - Chengdu first saw a billion-yuan company in 2015, but the milestone was short-lived, with the market capitalization of Guojin Securities dropping below 500 billion yuan within six months [2][3] - From 2015 to 2019, the market capitalization rankings were dominated by Guojin Securities, ChuanTuo Energy, Kanghong Pharmaceutical, and Tongwei, with the top company fluctuating around 500 billion yuan [3][5] - The resurgence of billion-yuan companies began in 2020 with Tongwei surpassing 1 billion yuan, followed by a significant increase in market capitalization for other companies [5][6] Emerging Companies and Industries - New entrants to the billion-yuan market include Xinyi and Baili Tianheng, which represent new industries such as AI, photovoltaic energy, and innovative pharmaceuticals [8][9] - Xinyi specializes in optical modules, facilitating high-speed data transmission, while Baili Tianheng focuses on innovative ADC drug development for cancer treatment [9][10] - Chengdu's industrial landscape is evolving, with the city launching a future industry fund aimed at sectors like humanoid robots and gene therapy, indicating a strategic push towards innovation [10][13] Industry Development - Chengdu has established itself as a hub for electronic information and innovative pharmaceuticals, with significant investments and a growing number of listed companies in these sectors [12][13] - The city has developed two trillion-yuan industrial clusters and several other significant industry clusters, showcasing its capacity for economic growth and innovation [13][14] - The presence of long-established companies in these sectors, such as Tongwei and Baili Tianheng, highlights the importance of sustained investment and development in achieving high market valuations [12][14]

Core Insights - Chengdu's local listed companies achieved a historic milestone in August with the emergence of two companies, Xinyi Technology and Baili Tianheng, surpassing a market capitalization of 100 billion yuan, marking the first time the city has seen "double billion" companies [1][5] - The market capitalization is a crucial indicator of a listed company's overall strength, and billion-yuan companies remain rare among over 5,000 listed companies in A-shares [1][5] - The ranking of Chengdu's listed companies has undergone significant changes, influenced by factors beyond just market valuation [1][5] Market Capitalization Rankings - As of August 26, the top ten Chengdu listed companies by market capitalization are: 1. Xinyi Technology: 2802.67 billion yuan 2. Baili Tianheng: 1363.40 billion yuan 3. Tongwei Co., Ltd.: 959.82 billion yuan 4. Chuan Investment Energy: 757.51 billion yuan 5. Chengdu Bank: 756.98 billion yuan 6. Sichuan Road and Bridge: 750.81 billion yuan 7. Dongfang Electric: 675.92 billion yuan 8. Kelun Pharmaceutical: 610.46 billion yuan 9. Shenghe Resources: 413.67 billion yuan 10. Zhong Wuyun Drone: 390.83 billion yuan [1][7] Historical Context - The first billion-yuan company in Chengdu was Guojin Securities, which reached a market cap of 1027.68 billion yuan in June 2015 but did not maintain this status for long [3][4] - From 2015 to 2019, the market capitalization rankings were dominated by four companies: Guojin Securities, Chuan Investment Energy, Kanghong Pharmaceutical, and Tongwei Co., Ltd., with market caps around 500 billion yuan [3][4] - In 2020, Tongwei Co., Ltd. broke the billion-yuan mark again, reaching 1730.4 billion yuan by year-end, leading to a new competitive landscape [4][5] New Entrants and Industries - The recent rankings feature new entrants such as Baili Tianheng, Xinyi Technology, and Jiachitech, with many companies representing emerging industries like AI, photovoltaic new energy, and innovative pharmaceuticals [8][9] - Xinyi Technology specializes in optical modules, facilitating data transmission in the digital world, while Baili Tianheng focuses on innovative ADC drug development for cancer treatment [9][10] Industrial Development - Chengdu has launched a future industry fund with an initial scale of 112 billion yuan, targeting sectors like humanoid robots, next-generation mobile communications, and gene therapy [10][15] - The city has developed two trillion-yuan industrial clusters in electronic information and equipment manufacturing, along with several other significant industry clusters [14][15]